A Life Sciences investment firm in the USA is raising an impact-focused fund with an expected first close of $50M USD in late 2023, to target life sciences companies addressing critical health disparities in the US and globally.
The firm leverages venture creation and private equity strategies to create nimble and focused pre-seed to seed-stage companies with aligned interests, providing resources and expertise that allow these companies to develop quickly. This also includes externalizing undervalued assets that meet its thesis in public and late-stage platform companies for rapid development.
The investment size is within the $5M-10M range across an investment cycle, and the firm anticipates deploying 3-5 companies within the next year.
The firm will consider therapeutics, diagnostics, and medical devices that advance health equity. The firm does not consider digital health. Within therapeutics, the firm is modality-agnostic and looks at technologies from Pre-clinical to Phase 2. Within diagnostics and medical devices, the firm is opportunistic and looks at technologies in development and clinical phases. The firm is open to all indications that address the needs of underserved minorities.
The firm adopts a case-by-case approach, so has no preliminary requirements of the management team. The firm prefers to lead its early rounds and require board seating.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment